BioCentury | Dec 6, 2010
Clinical News

Cel-Sci preclinical data

...In a mouse model of collagen-induced arthritis, a single dose of CEL-2000 formulated with DepoVax delivery...
...slowed the progression of RA and significantly reduced Arthritic Index (AI) scores vs. untreated controls. CEL-2000...
...a target antigen and adjuvant into an oil depot. Cel-Sci Corp. (NYSE-A:CVM), Vienna, Va. Product: CEL-2000...
BioCentury | Oct 26, 2009
Clinical News

Cel-Sci preclinical data

...In mice, CEL-2000 significantly reduced joint inflammation as measured by visual inspection and foot pad thickness...
...at the American College of Rheumatology meeting in Philadelphia. Cel-Sci Corp. (NYSE-A:CVM), Vienna, Va. Product: CEL-2000...
BioCentury | Sep 15, 2008
Clinical News

Cel-Sci preclinical data

...In a mouse model of RA, CEL-2000 was as good as Enbrel etanercept in slowing disease...
...in the U.S. and Canada with Wyeth (NYSE:WYE, Madison, N.J.), which holds exclusive rights elsewhere. CEL-2000...
...System ( L.E.A.P.S. ) T cell modulation platform technology. Cel-Sci Corp. (AMEX:CVM), Vienna, Va. Product: CEL-2000...
Items per page:
1 - 3 of 3